THIS IS A SOURCES SOUGHT NOTICE ONLY. THIS IS NOT A REQUEST FOR PROPOSAL. The Department of Veterans Affairs, VHA, Network Contracting Office (NCO) 19 Rocky Mountain Acquisition Center is seeking potential sources that are capable of providing, referral laboratory testing services including: immunohistochemical (IHC) stains, special stains, diagnostic and prognostic markers for breast cancer prognosis to include interpretation, IHC breast assays, HER2 Profiling, micrometastasis analysis, gastric cancer profile, molecular PCR pathway testing, mismatch repair (MMR)/microsatellite instability (MSI), diagnostic and prognostic molecular testing for all types of malignancy and other specialty testing, on a cost per test (CPT) basis. This requirement is for the following VISN 19 facilities: VA Eastern Colorado Health Care System, 1700 North Wheeling Street, Aurora, CO, 80045. NCO 19 is performing market research to determine if there is a sufficient number of qualified (1) Service-Disabled Veteran Owned Small Business (SDVOSB); (2) Veteran Owned Small Business (VOSB); (3) Small or emerging small business firms; or (4) Large businesses who can fulfill the requirement. This Sources Sought notice is issued for the purpose of market research in accordance with Federal Acquisition Regulation (FAR) Part 10. All SDVOSB, VOSB, small and large businesses capable of fulfilling the requirement are invited to respond. NAICS code to be used for this acquisition is 621511. All interested firms who can meet the requirements stated in Summary of Requirements below should respond, in writing, with the following information: Interest and Capabilities Address and DUNS Business category (SDVOSB, VOSB, Small Business, or Large Business) State if interested firm has a NAC or GSA contract by replying with their applicable contract number Any information submitted by respondents to this sources sought synopsis is voluntary. This sources sought notice is not to be construed as a commitment by the Government, nor will the Government reimburse any costs associated with the submission of information in response to this notice. Respondents will not individually be notified of the results of any Government assessments. Responses and questions may be submitted electronically to: [email protected] in a Microsoft word compatible format no later than Tuesday, February 4th, 2020 at 12:00pm Mountain Time. PHONE CALLS NOT ACCEPTED. SUMMARY OF REQUIREMENTS: The contractor shall provide: referral laboratory testing services including immunohistochemical (IHC) stains, special stains, diagnostic and prognostic markers for breast cancer prognosis to include interpretation, IHC breast assays, HER2 Profiling, micrometastasis analysis, gastric cancer profile, molecular PCR pathway testing, mismatch repair (MMR)/microsatellite instability (MSI), diagnostic and prognostic molecular testing for all types of malignancy and other specialty testing, on a cost per test basis. The contractor shall meet the performance characteristics for accuracy and precision as defined by the 1988 Clinical Laboratory Improvement Act (CLIA) and the Clinical and Laboratory Standards Institute (CLSI). The contractor must be CLIA (Clinical Laboratory Improvement Act) and College of American Pathologists (or equivalent) certified. The Contractor shall be HIPAA (Health Insurance Portability and Accountability Act) compliant. The contractor must have the required tests available with accompanying Current Procedural Terminology (CPT) codes. The contractor must have the ability to perform all tests listed without splitting the specimen The contractor must have the ability to perform all tests without sending the specimens to subcontracted labs for testing, since these are irretrievable specimens from surgical/invasive procedures and cannot be recollected. *** Contractor shall have the ability to provide ALL the listed tests, specimens and stains below, Tables 1-4 *** TABLE 1: Stain and Specialized Tests Line Item Tests (Stain and Specialized) 1 Mammostrat  2 KRAS by PCR     3 EGFR by PCR  4 ALK FISH  5 BRAF V600 Mutation   6 BRAF by PCR   7 EGFR by FISH  8 MMR global 9 Her 2 neu global  10 Her 2 neu FISH 11 ER global   12 PR global  13 MSI by PCR  14 Kappa FISH (stain only) 15 Lambda FISH (stain only) Immunostains See Table 2 Below TABLE 2: Immunostains (Stain and Specialized) Line Item Immuno Stains 16 AACT 17 AAT 18 ACTH 19 Actin (MSA) 20 Actin (SMA) 21 Adenovirus 22 AE1/AE3(pan-CK) 23 AFP, ALK-1 24 Amyloid A, 25 ß-Amyloid P 26 AR, B72.3 27 B-Amyloid 28 BCA-225, 29 BCL1, 30 Cyclin D1 31 BCL2, BCL6 32 BerEP4 33 Beta-Catenin 34 BE-8, BOB1, 35 BRCA1 36 Breast Triple Stain 37 CA15.3 38 CA19.9 39 CA125 40 Calcitonin 41 Caldesmon 42 Claponin 43 Calretinin 44 CAM 5.2, 45 Cathepsin D 46 Cat Scratch 47 Cyclin D1/BCL1 48 CD1a 49 CD2 50 CD3 51 CD4 52 CD5 53 CD7 54 CD8 55 CD10 56 CD11c 57 CD14 58 CD15 59 CD19 60 CD20 61 CD21 62 CD22 63 CD23 64 CD25 65 CD30 66 CD31 67 CD33 68 CD34 69 CD35 70 CD38 71 CD42b 72 CD43 73 CD45 74 CD45RB 75 CD45RO 76 CD56 77 CD57 78 CD61 79 CD68 80 CD74 81 CD75 82 CD79a 83 CD99 84 CD117(C-KIT) 85 CD123 86 CD138 87 CD163 88 CDX2 89 CDX2/CK7 90 CEA monoclonal 91 CEA polyclonal 92 Chromogranin A 93 CK5 94 CK5/6 95 CK7 96 CK8 97 CK14 98 CK17 99 CK18 100 C19 101 CK20 102 CK903(CK-HMW) 103 CK-Double Stain (HMW/LMW) 104 CK OSCAR (pan-CK) 105 CMV, Collagen IV 106 COX2 107 CXCR4 108 Cyclin E 109 D2-40 110 DBA.44 111 DCC 112 Desmin 113 DOG1 114 DPC4 (SMADU) 115 EBV(LMP-1) 116 E-Cadherin 117 elF4E 118 EGFR 119 EMA 120 ER 121 ERCC1 122 Factor VIII 123 Factor XIIIa 124 Fascin 125 Fli-1 126 FOX P3 127 FSH 128 GCDFP-15 129 GFAP 130 GH 131 Gastrin 132 Glucagon 133 GST 134 Glycophorin-A 135 Glypican-3 136 Granzyme 137 H.Pylori 138 HBVc 139 HBVs 140 HBME-1 141 HER2(hercepTest) 142 HCG 143 Hemoglobin A 144 HepPar-1 145 HHV8 146 HPV 147 HLA-DR 148 HMB-45 149 HAFG2 150 HPL 151 HSV I 152 HSV II 153 IgA 154 IgD 155 IgG 156 IgG4 157 IgM 158 Inhibin 159 Insulin 160 Kappa 161 Ki-67 162 Ki-67/Caspase-3 163 LH 164 Lambda 165 Lysozyme 166 Mammaglobin 167 Melan A 168 Mesothelin 169 MGMT 170 MITF 171 MOC-31 172 MSH2 173 MSH6 174 MDR 175 MLH1 176 M PO 177 mTOR 178 MUC-1 179 MUC-2 180 MUC-5 181 MUC-6 182 MUM1 183 MyoD1 184 Myogenin 185 Myoglobin 186 Napsin A 187 NB 188 NF 189 NSE 190 2-Oct 191 4-Oct 192 p16 193 p21 194 p27 195 p53 196 p57 197 p63 198 p120(caterin) 199 p501S 200 p504S 201 Pakt 202 Pan Melanoma 203 Parvovirus 204 PAX2 205 PAX5 206 PD1 207 PDGFRA 208 PDGFRB 209 Perforin 210 PHH3 211 PLAB 212 P.Carinii 213 PMS2 214 PP 215 PR 216 Prealbumin (TTR) 217 Prolactin 218 Prostate Triple Stain 219 PSA 220 PSAP/HPAP 221 PTEN 222 PTH 223 RCC1 224 S100 225 Serotonin 226 SMMHC 227 Somatostatin 228 Surfactant 229 Spirochete 230 Survivin 231 Synaptophysin 232 Tau 233 TdT 234 TM 235 TGB 236 TGF- 237 TRAP 238 TS 239 TSH 240 TTF-1 241 TIA-1 242 Toxoplasma 243 Tryptase 244 Tuberculosis 245 Tyrosinase 246 Uroplakin III 247 VEGF 248 Villin 249 Vimenti 250 Wilm's Tumor (WT-1) 251 ZAP-70 TABLE 3: Hematopathology (Specialized) Line Item Hematopathology Tests (Specialized) 252 Flow Cytometry Panels 253 FISH (Hematologic, Plasma Cell) 254 Individual Probes 255 Cytogenetics 256 Molecular Genetic Testing 257 Cancer Profiles 258 Liquid Biopsy Testing TABLE 4: Solid Tumor Table (Specialized) Line Item Solid Tumor (Specialized) 259 Consultation 260 Cancer Profiles 261 Prostate Cancer Testing 262 Breast Cancer Testing 263 Colon Cancer 264 Sarcoma 265 Brain Cancer 266 Bladder Cancer 267 GI Cancer 268 Melanoma 269 Lung Cancer (End of Document)

Bid Protests Not Available